中国临床药理学杂志2025，Vol.41Issue(5)：601-605,5.DOI:10.13699/j.cnki.1001-6821.2025.05.001
依洛尤单抗联合匹伐他汀钙治疗急性冠状动脉综合征PCI术后患者的临床研究
Clinical trial of evolocumab combined with pitavastatin calcium in the treatment of patients with acute coronary syndrome after PCI
摘要
Abstract
Objective To observe the clinical efficacy and safety of evolocumab injection combined with pitavastatin calcium tablets in the treatment of patients with acute coronary syndrome after percutaneous coronary intervention(PCI).Methods According to cohort method,the patients with acute coronary syndrome after PCI were divided into control group and treatment group.Two groups were treated with routine treatment(anti-platelet,anti-coagulation,reducing myocardial oxygen consumption,improving myocardial ischemia).On the routine treatment,control group was treated with pitavastatin calcium 2 mg per time,once a day,orally before bedtime.On the basis of control group,treatment group was given evolocumab 140 mg per time,once every 2 weeks,subcutaneous injection.Two groups were treated for 6 months.The clinical efficay,blood lipid,myocardial injury indexes,serum levels of amyloid A1(SAA1)and Gla-rich protein(GRP),major adverse cardiovascular events(MACES)and safety were compared between two groups.Results Fifty-two patients were enrolled in the treatment group and 58 patients were enrolled in the control group.After treatment,the total effective rates of treatment and control groups were 94.23％(49 cases/52 cases)and 75.86％(44 cases/58 cases),and the difference was statistically significant(P＜0.05).After treatment,the total cholesterol levels of treatment and control groups were(1.17±0.22)and(1.35±0.25)mmol·L-1,triglyceride levels were(2.63±0.76)and(3.89±0.92)mmol·L-1,high-density lipoprotein cholesterol levels were(1.41±0.30)and(1.26±0.28)mmol·L-1,low-density lipoprotein cholesterol levels were(1.23±0.46)and(1.58±0.55)mmol·L-1,cardiac troponin Ⅰ levels were(0.03±0.01)and(0.05±0.02)ng·mL-1,creative kinase isoenzyme levels were(12.35±2.38)and(14.23±2.89)U·L-1,SAA1 levels were(213.92±41.58)and(274.18±43.36)μg·mL-1,GRP levels were(21.32±3.50)and(19.35±3.27)ng·mL-1,incidences of MACEs were 9.62％and 24.14％,the differences were statistically significant between two groups(all P＜0.05).The adverse drug reactions of two groups were fatigue,pruritus,abdominal pain and elevated aminotransferase.There was no significant difference in total incidences of adverse drug reactions between treatment group and control group(11.54％vs 13.79％,P＞0.05).Conclusion Evolocumab injection combined with pitavastatin calcium tablets has a definitive clinical efficacy in the treatment of patients with acute coronary syndrome after PCI,which can effectively reduce the blood lipid levels,the incidence of MACEs and myocardial injury,regulate the serum levels of SAA1 and GRP,without increasing the incidence of adverse drug reactions.关键词
依洛尤单抗注射液/匹伐他汀钙片/急性冠状动脉综合征/经皮冠状动脉介入治疗/安全性评价Key words
evolocumab injection/pitavastatin calcium tablet/acute coronary syndrome/percutaneous coronary intervention/safety evaluation分类
药学引用本文复制引用
李萌,闫小菊,苏亚坤,张慧晶..依洛尤单抗联合匹伐他汀钙治疗急性冠状动脉综合征PCI术后患者的临床研究[J].中国临床药理学杂志,2025,41(5):601-605,5.基金项目
衡水市科技计划基金资助项目(2021014086Z) （2021014086Z）
